Filing Flows

Filing Flows › Agios Pharmaceuticals (AGIO) › Next earnings date

Agios Pharmaceuticals (AGIO) earnings: beat the estimate

Agios Pharmaceuticals (AGIO) reported on Nov 5, 2026 and beat the EPS estimate: −$1.09 against −$1.23 (+11.4%). Revenue was $55.4M for Q3 2026, +330% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+11.4% vs estimate
Beat rate80%

The last report

Agios Pharmaceuticals reported revenue of $55.4M for the third quarter 2026 (+330% Y/Y), net loss $65.0M. How it makes money → · Every quarter →

Agios Pharmaceuticals: EPS against the estimate, last 5 reportsAgios Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$1.90−$1.78Oct 25−$1.95−$1.85Feb 26−$1.79−$1.69Apr 26−$1.67−$1.69Jul 26−$1.23−$1.09Nov 26
Latest (Nov 26): Estimate −$1.23, Reported −$1.09.
AGIO: the stock's move on each reportAGIO: the stock's move on each reportJul 30, 2026-14.3%Apr 29, 2026+12.9%Feb 12, 2026+0.9%Oct 30, 2025+3.1%

Agios Pharmaceuticals' latest quarter

Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.

Questions

Did Agios Pharmaceuticals beat earnings?

Agios Pharmaceuticals (AGIO) reported on Nov 5, 2026 and beat the EPS estimate: −$1.09 against −$1.23 (+11.4%).

When does AGIO report earnings?

The next date is not set yet.

Does Agios Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.